Bioactive peptides in therapeutic α1-Antitrypsin preparations modulate neutrophil chemokine receptors: Implications for augmentation therapy - 30/01/26
Doi : 10.1016/j.resmer.2026.101249
Julia Held a, b, Jing Liu a, b, Friedemann R. Börner c, Michael Kiehntopf c, Sabine Wrenger a, b, Sabina Janciauskiene a, b, ⁎ 
a Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Germany
b Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research DZL, Hannover, Germany
c Institute of Clinical Chemistry and Laboratory Diagnostics, Jena University Hospital, Jena, Germany
⁎ Correspondence author at. Department of Respiratory Medicine and Infectious Diseases. Department of Respiratory Medicine and Infectious Diseases
Plan
| Take home message: C-terminal peptides in AAT therapy formulations modulate neutrophil chemokine receptors, suggesting these fragments may influence the immunological effects and therapeutic outcomes of AAT augmentation. |
© 2026
The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 89
Article 101249- mai 2026 Retour au numéro
Article précédent
- Interstitial lung disease mortality rates and disparities across U.S. states
- Eva Ma, Pengyi Zhu, Niranjan Jeganathan
- Serum concentration of Surfactant protein D at diagnosis is associated with malnutrition in patients with idiopathic pulmonary fibrosis
- Laurent Vernhet, Cédric Ménard, Chloé Rousseau, Stéphane Jouneau
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?